Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
Lin, Simeng, Kennedy, Nicholas A, Saifuddin, Aamir, Sandoval, Diana Muñoz, Reynolds, Catherine J, Seoane, Rocio Castro, Kottoor, Sherine H, Pieper, Franziska P, Lin, Kai-Min, Butler, David K, Chanchlani, Neil, Nice, Rachel, Chee, Desmond, Bewshea, Claire, Janjua, Malik, McDonald, Timothy J, Sebastian, Shaji, Alexander, James L, Constable, Laura, Lee, James C, Murray, Charles D, Hart, Ailsa L, Irving, Peter M, Jones, Gareth-Rhys, Kok, Klaartje B, Lamb, Christopher A, Lees, Charlie W, Altmann, Daniel M, Boyton, Rosemary J, Goodhand, James R, Powell, Nick, Ahmad, Tariq
Published in Nature communications (16.03.2022)
Published in Nature communications (16.03.2022)
Get full text
Journal Article
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Liu, Zhigang, Le, Kaixing, Zhou, Xin, Alexander, James L, Lin, Simeng, Bewshea, Claire, Chanchlani, Neil, Nice, Rachel, McDonald, Timothy J, Lamb, Christopher A, Sebastian, Shaji, Kok, Klaartje, Lees, Charlie W, Hart, Ailsa L, Pollok, Richard C, Boyton, Rosemary J, Altmann, Daniel M, Pollock, Katrina M, Goodhand, James R, Kennedy, Nicholas A, Ahmad, Tariq, Powell, Nick
Published in The lancet. Gastroenterology & hepatology (01.02.2023)
Published in The lancet. Gastroenterology & hepatology (01.02.2023)
Get more information
Journal Article